SCHEMBL10190233

SCHEMBL10190233

CC(C)(C)OC(=O)N1CC(C(F)F)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.50
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 1/20 0.41
RORC P51449 1/20 0.41
RECQL P46063 1/20 0.40
EPHX1 P07099 1/20 0.40
DPP4 P27487 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
NAMPT P43490 1/20 0.39
USP30 Q70CQ3 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21910046 0.87 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL23523667 0.86 HPGD (0.48) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL26100661 0.86 NR1H2 (0.60) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL16338237 0.86 HPGD (0.48) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL16338236 0.86 HPGD (0.48) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL25072009 0.86 NR1H2 (0.46) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL28600836 0.84 ALDH1A1 (0.51) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL26709621 0.84 ALDH1A1 (0.51) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL23880037 0.83 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC
SCHEMBL4546637 0.83 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175043-A1 PYRIDOPYRIMIDINE DERIVATIVE AND USE THEREOF 广东东阳光药业股份有限公司 2024-08-29 WO disclosed
EP-2590969-B1 Therapeutic agents 976 ASTRAZENECA AB (SE) 2014-10-15 EP disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
WO-2012004588-A2 THERAPEUTIC AGENTS 976 ASTRAZENECA AB (SE) 2012-01-12 WO disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS TYR, MC2R, MC1R NR1H2 972/4885USP2 3832/4885SMN1; SMN2 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.